BIOXYTRAN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 USD | -11.11% |
|
-9.43% | -20.00% |
| Apr. 19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 22 | Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 43.4 | 24.56 | 23.39 | 44.34 | 59.05 | 21.85 |
| Enterprise Value (EV) 1 | 43.59 | 25.24 | 24.96 | 46.39 | 60.92 | 23.75 |
| P/E ratio | -146 x | -13.1 x | -9.09 x | -10.5 x | -22.4 x | -4.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | -28,544,102 x | -6,215,798 x |
| EV / FCF | -430 x | 109 x | -30.1 x | -32.4 x | -71.2 x | -9.91 x |
| FCF Yield | -0.23% | 0.92% | -3.32% | -3.09% | -1.4% | -10.1% |
| Price to Book | -193 x | -30.7 x | -8.27 x | -16.1 x | -21.9 x | -8.99 x |
| Nbr of stocks (in thousands) | 85,104 | 86,476 | 97,451 | 110,841 | 123,014 | 145,642 |
| Reference price 2 | 0.5100 | 0.2840 | 0.2400 | 0.4000 | 0.4800 | 0.1500 |
| Announcement Date | 3/13/19 | 3/18/20 | 4/9/21 | 4/11/22 | 3/31/23 | 3/22/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | - | -2.134 | -3.82 |
| EBIT 1 | -0.2147 | -1.631 | -1.269 | -4.214 | -2.138 | -3.828 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.296 | -1.858 | -2.543 | -4.528 | -2.657 | -4.37 |
| Net income 1 | -0.2964 | -1.858 | -2.481 | -4.032 | -2.464 | -4.28 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.003483 | -0.0217 | -0.0264 | -0.0379 | -0.0214 | -0.0319 |
| Free Cash Flow 1 | -0.1013 | 0.2314 | -0.8295 | -1.432 | -0.8554 | -2.395 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/13/19 | 3/18/20 | 4/9/21 | 4/11/22 | 3/31/23 | 3/22/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.19 | 0.68 | 1.57 | 2.05 | 1.87 | 1.9 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.8761 x | -0.4971 x |
| Free Cash Flow 1 | -0.1 | 0.23 | -0.83 | -1.43 | -0.86 | -2.4 |
| ROE (net income / shareholders' equity) | 262% | 363% | 186% | 178% | 82.4% | 136% |
| ROA (Net income/ Total Assets) | -735% | -796% | -290% | -1,182% | -545% | -941% |
| Assets 1 | 0.0403 | 0.2333 | 0.8541 | 0.3411 | 0.452 | 0.4548 |
| Book Value Per Share 2 | -0 | -0.0100 | -0.0300 | -0.0200 | -0.0200 | -0.0200 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/13/19 | 3/18/20 | 4/9/21 | 4/11/22 | 3/31/23 | 3/22/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 21M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BIXT Stock
- Financials Bioxytran, Inc.
